What Is the Nocebo Effect and Why Negative Expectations Cause Real Harm

Published 2026-04-14 · Updated 2026-04-15

✓ Fact-checked by the Kalenux editorial team

In the late 1990s, a man in a clinical trial swallowed 29 pills, believing they were antidepressants. His blood pressure dropped, his breathing became shallow, and he arrived at the emergency room nearly unconscious. Doctors found no toxic levels of any substance in his blood. The pills were placebos. He had attempted suicide with sugar tablets — and his body had responded accordingly.

This is the nocebo effect in its most dramatic form: the capacity of the mind to generate real, measurable physical harm from nothing more than negative expectation.

What the Nocebo Effect Is

The term comes from the Latin nocebo, meaning "I shall harm" — the direct counterpart to placebo, "I shall please." While placebo research has a history stretching back to the 1950s, systematic investigation of nocebo was largely neglected until the 1990s, when researchers began noticing that the same mechanism producing benefit could just as easily produce harm.

The nocebo effect occurs when a person's negative expectations, fears, or beliefs about a treatment or situation cause real physiological deterioration. The harm is not imaginary, not feigned, and not attributable to the direct pharmacological action of any substance. It is a genuine biological event produced by anticipation.

The distinction from hypochondria or malingering is important. Nocebo responses involve measurable physiological changes — altered hormone levels, changed pain thresholds, modified immune responses — not merely subjective self-reports of discomfort.

The researcher Fabrizio Benedetti at the University of Turin has spent more than two decades systematically characterizing nocebo mechanisms. His work, along with that of Tor Wager at Columbia, Ted Kaptchuk at Harvard, and Luana Colloca at the University of Maryland, has transformed nocebo from a clinical curiosity into one of the most well-characterized examples of mind-body interaction in all of medicine.

A Brief History of Nocebo Research

The conceptual counterpart to placebo was formally named in a 1961 paper by Walter Kennedy, who introduced the term "nocebo" to describe harmful effects produced by inert interventions. But systematic research lagged decades behind placebo work. Several reasons explain this neglect.

First, medical ethics made direct experimental induction of harm more problematic than induction of benefit. Second, the cultural and commercial investment in drug efficacy research meant that beneficial placebo effects were of more obvious practical interest to pharmaceutical companies and regulators. Third, the reductionist model that dominated medicine for much of the twentieth century made mind-mediated physical effects conceptually awkward — it was easier to dismiss them as subjective or psychological.

The shift began in the 1990s as neuroimaging made it possible to observe brain processes during expectation and as pharmacological studies began identifying specific molecular pathways through which expectation altered physiological states. Once nocebo effects could be attributed to specific, nameable biological mechanisms — cholecystokinin, opioid systems, HPA axis activation — they became scientifically respectable in a way that "psychological" explanations had not previously been.

The turning point came with a series of papers by Benedetti and colleagues in the early 2000s that characterized nocebo hyperalgesia (expectation-induced pain amplification) at a molecular level, demonstrating that nocebo was not merely behavioral but was the output of specific, measurable biological cascades.

The Biology of Negative Expectation

For decades, skeptics dismissed placebo and nocebo effects as "just psychological." Neuroimaging and pharmacological studies have since dismantled that framing. The brain does not distinguish cleanly between expected harm and actual harm. Expectation activates many of the same neural circuits as the real thing.

What Happens in the Brain and Body

When a person anticipates pain, nausea, or illness, several systems activate:

The hypothalamic-pituitary-adrenal (HPA) axis releases cortisol and other stress hormones. These are the same hormones released under genuine physical threat. Elevated cortisol suppresses immune function, raises blood pressure, increases inflammation, and impairs healing.

Anticipatory anxiety circuits in the prefrontal cortex and amygdala enter a state of heightened vigilance. Interoceptive signals from the body are amplified — the brain becomes more sensitive to the very sensations it is expecting to detect.

Cholecystokinin (CCK), a neuropeptide, appears to be a key chemical mediator of nocebo hyperalgesia (increased pain sensitivity from negative expectation). In a landmark study by Benedetti et al. (2006), researchers induced nocebo hyperalgesia in subjects and then administered proglumide, a CCK antagonist. The nocebo pain response was completely blocked. This is powerful evidence that nocebo effects are biological, not merely psychological — a specific pharmacological antagonist eliminated the effect, just as it would with a directly administered drug.

Endogenous opioid activity decreases under nocebo conditions. The brain's own pain-suppression system is partially deactivated by negative expectation — the inverse of what happens during placebo analgesia. This has been confirmed by studies using naloxone (an opioid antagonist) that show the opioid system is active in placebo analgesia but suppressed during nocebo hyperalgesia.

Dopaminergic signaling is also affected. The brain's reward and anticipation systems respond to negative expectation by reducing the tonic dopaminergic activity associated with positive anticipation — contributing to the subjective quality of dread and the cognitive focus on anticipated harm.

"The nocebo effect tells us that the environment, words, and context surrounding treatment are not merely decorative. They are themselves pharmacologically active." — Fabrizio Benedetti, University of Turin, one of the world's leading placebo and nocebo researchers

The practical significance of this biological cascade is profound. When a patient is told "this will hurt a lot" or reads a list of side effects including severe pain, nausea, and dizziness, they are not simply receiving information. They are receiving a biological input that activates a cascade of changes in pain sensitivity, hormonal state, immune function, and neural anticipatory activity. The words are drugs.

Warning Labels and Induced Side Effects

Perhaps the most practically important manifestation of nocebo occurs in clinical medicine: patients who read or hear about a drug's possible side effects are more likely to experience those effects.

The Finasteride Study

A 2009 study published in the Journal of Sexual Medicine examined men taking finasteride for benign prostatic hyperplasia. The study compared two groups:

Group A: told about possible sexual dysfunction before treatment
Group B: not informed of sexual side effects

Result: Sexual dysfunction occurred in 43.6% of Group A versus 15.3% of Group B — a nearly threefold difference. The drug was identical. The information was the variable.

This study is often cited because the effect size is so large that alternative explanations become implausible. A threefold difference in adverse event rates from the same drug, in comparable populations, driven entirely by information disclosure, cannot be explained by pharmacological variation.

Beta-Blocker Side Effects

A meta-analysis by Meijer et al. (2018) reviewed studies of beta-blockers, commonly prescribed for heart conditions. Beta-blockers can cause fatigue and sexual dysfunction. Studies consistently found that patients who were informed of these possibilities reported them at significantly higher rates than patients in trials who were not informed. Again, same drug, different expectation, different outcome.

The Aspirin Problem

Even aspirin is not immune. When patients are told aspirin might cause stomach irritation, their stomach irritation rates rise. The gastrointestinal side effect profile of aspirin changes based on what patients have been led to expect.

Drug Category	Study	Nocebo Effect Found
Finasteride (BPH)	Mondaini et al. 2009	Sexual dysfunction: 43.6% vs 15.3%
Beta-blockers	Meijer et al. 2018	Fatigue and dysfunction: consistently higher with disclosure
Statins	Gupta et al. 2017 SAMSON trial	Muscle pain: 90% of statin symptoms were nocebo
Antidepressants	Rief et al. 2015	Nausea and headache rates significantly nocebo-mediated
COVID-19 vaccines	Haas et al. 2022	Up to 76% of systemic side effects may be nocebo
Aspirin	Bingel et al. 2011	GI irritation rates elevated with negative framing

The SAMSON trial (2020) deserves particular attention. It was a rigorous double-blind crossover trial of statin side effects. Participants who had stopped statins due to muscle pain were given either statins or identical placebos in randomized order. Nocebo accounted for 90% of the muscle pain attributed to statins. This is a major finding with direct public health implications: millions of people may be avoiding a medication that would benefit their cardiovascular health because of nocebo-induced pain.

The researchers calculated that if statin non-adherence attributable to nocebo-induced muscle pain were reversed through better informed consent practices, the cardiovascular benefits in the population would be equivalent to a significant reduction in heart attack and stroke incidence. The nocebo effect has measurable public health costs at scale, not just individual costs in clinical encounters.

The COVID-19 Vaccine Evidence

The Haas et al. (2022) study published in JAMA Internal Medicine analyzed side effect reports from COVID-19 vaccine trials and found that up to 76% of systemic side effects — fatigue, headache, malaise — reported after COVID-19 vaccination could be attributed to nocebo rather than to the active vaccine ingredient. Participants receiving placebo injections reported these effects at rates that accounted for the majority of the total reported in vaccine arms.

This finding does not diminish vaccine safety or efficacy. It demonstrates that the context of vaccination — the awareness of what might happen, the anxiety around the injection, the media coverage of vaccine reactions — is a biologically active input that shapes the physiological response independently of the vaccine's pharmacological action.

Nocebo in Drug Trials: The Inactive Control Problem

Clinical trials that use placebo controls consistently document adverse events in placebo groups. These "placebo adverse events" are a measure of nocebo.

A systematic review by Mitsikostas et al. (2011) analyzed 40 randomized controlled trials in neurology. In placebo groups:

Headache was reported by 7% of participants
Nausea by 5%
Dizziness by 4%
Fatigue by 5%

The participants received no active substance. They had simply enrolled in a trial, read the informed consent disclosure of possible side effects, and subsequently experienced those effects at meaningful rates.

This has a methodological implication that extends beyond medicine: the act of asking people whether they have experienced a symptom can increase the probability that they will experience it. Survey instruments, informed consent procedures, and even symptom checklists can create the conditions for nocebo.

The methodological challenge this creates for clinical trials is substantial. When placebo arms show meaningful adverse event rates, accurately estimating the net adverse event burden of an active drug requires subtracting the nocebo contribution — which requires specifically designed study arms to estimate. Standard two-arm trials comparing active drug to placebo confound the drug's pharmacological adverse effects with the nocebo contribution of the disclosure process and trial participation itself.

A 2013 paper by Colloca and Miller in Theoretical Medicine and Bioethics proposed revised frameworks for understanding placebo-controlled trial data that explicitly account for nocebo contributions, arguing that ignoring nocebo leads to both underestimation of drug benefit (because some placebo benefit is genuine nocebo reduction) and overestimation of drug harm (because some adverse effects in active arms are nocebo not pharmacology).

The Role of Doctor-Patient Communication

What a clinician says — and how they say it — can cause harm.

Framing Effects in Clinical Practice

Research by Koyama et al. and others has shown that simple word choice produces measurable differences in pain experience. Patients told "This will hurt a lot" before a procedure report higher pain than patients told "You will feel some pressure." Same procedure. Same needle. Different words.

A 2010 study by Varelmann et al. compared two ways of delivering an epidural:

Negative frame: "You are going to feel a big bee sting; this is the worst part of the procedure."
Positive frame: "We are going to give you a local anesthetic that will numb the area."

Patients in the negative-frame group reported significantly higher pain scores. The magnitude of the framing effect was clinically meaningful — not a small laboratory finding but a difference large enough to matter in a real clinical encounter.

More broadly, research on the neurolinguistics of clinical communication has found that certain words reliably activate threat-detection circuits: "sharp," "burning," "severe," "dangerous," "worse." These words are not neutral information carriers — they are biological inputs that alter the physiological state of the listener before any procedure has occurred.

Informed consent is a cornerstone of medical ethics, requiring that patients understand the risks and benefits of any intervention. But detailed disclosure of side effects can produce those side effects through nocebo mechanisms.

This is not a reason to abandon informed consent. It is a reason to think carefully about how disclosure is framed. Research suggests that:

Positive framing ("most people tolerate this well") produces fewer nocebo effects than negative framing ("some patients experience nausea")
Statistical framing ("1 in 100 people experience this") is less nocebo-inducing than listing symptoms without base rates
Contextualized disclosure that acknowledges side effects while emphasizing the benefits and the person's capacity to tolerate treatment appears to minimize nocebo without withholding information

A 2017 paper by Wells and Kaptchuk in the Journal of Pain proposed a framework they called "authorized non-deception" — structuring informed consent in ways that are fully honest but systematically minimize nocebo-inducing framing. Key elements include leading with benefit before risk, using natural frequency formats (1 in 100) rather than percentage formats, normalizing the experience of mild side effects without emphasizing severe ones disproportionately to their actual incidence, and explicitly building confidence in the patient's capacity to tolerate the treatment process.

Building Therapeutic Alliance as a Nocebo Countermeasure

The quality of the relationship between patient and clinician is itself a nocebo moderator. Patients with strong trust in their clinician show reduced nocebo responses compared to patients who feel dismissed, disrespected, or inadequately informed. This finding has been documented in multiple studies and has a plausible mechanism: perceived safety and trustworthiness activates parasympathetic responses that reduce the HPA axis activation underlying nocebo.

Kaptchuk et al.'s research at Harvard on therapeutic ritual and context effects has demonstrated that the style of clinical encounter — warm, curious, engaged versus efficient, distant, task-focused — produces different outcomes even when the same treatment is delivered. The relationship is pharmacologically active.

Mass Psychogenic Illness: Nocebo at Scale

The nocebo effect does not require individual expectation. It can propagate socially.

Mass psychogenic illness (sometimes called mass hysteria, though that term has been largely abandoned) occurs when groups of people develop genuine physical symptoms as a result of shared belief or social contagion. The symptoms are real — not faked — but have no identified environmental or biological cause.

Historic examples include:

The "dancing plague" of 1518 in Strasbourg, where hundreds of people danced uncontrollably for days
Factory illness outbreaks where workers in a plant develop symptoms after one worker collapses, with no identifiable toxin found
School illness clusters triggered by perceived odors or chemical exposures that laboratory testing cannot confirm
The 1962 June Bug epidemic in a US textile factory, extensively studied by sociologist Kerckhoff and Back, in which 62 workers reported symptoms of insect bites with no insect identified

More recent cases have been documented in military contexts, schools, and communities near perceived environmental hazards. The "wind turbine syndrome" debate involves claims that some individuals develop headaches, nausea, and sleep disturbance from turbine infrasound — effects that some researchers attribute to nocebo rather than to direct physiological impact, given that blinded studies have not reliably replicated the effect. A 2013 study by Chapman and colleagues found that participants exposed to infrasound or sham infrasound reported symptoms consistent with their belief about whether they were being exposed, not consistent with whether they actually were.

The sociological literature on mass psychogenic illness identifies consistent features: the illness spreads through visible observation of affected individuals, it is more common in enclosed social groups under stress, it preferentially affects those with closer social bonds to already-affected individuals, and it resolves when the group is separated and the transmission chain is broken.

These features suggest that nocebo transmission is social learning at its most visceral: seeing someone suffer activates preparatory responses in the observer that prepare the observer's own body for the same suffering. The same mirror-neuron and social-cognitive mechanisms that allow us to learn from observing others' experiences extend to observing their apparent harm responses.

The internet has created conditions for unprecedented scale of nocebo social transmission. Online communities documenting specific symptom clusters — whether around medications, devices, environmental exposures, or vaccines — create shared expectation frameworks that can shape physical experience across millions of people who have never met.

Nocebo in Everyday Life

The clinical and experimental literature is striking, but nocebo operates in ordinary life too.

Self-Fulfilling Health Beliefs

Research by Idler, Kaplan, and others has established that self-rated health is one of the strongest predictors of mortality, even when controlling for objective health status. People who believe themselves to be in poor health die earlier than people with equivalent clinical profiles who rate their health positively.

A study of men recovering from heart attacks found that those who believed themselves to be at high risk for further cardiac events — even when clinical risk profiles were similar — had higher mortality rates. The belief was independently predictive. This is one of the strongest naturalistic demonstrations of nocebo effects: the belief about health outcome shapes the health outcome.

A prospective study by Maruta and colleagues (2000) followed more than 800 patients over thirty years and found that pessimistic explanatory style — the tendency to interpret events in helpless, global, stable terms — predicted mortality independently of baseline health status. The relationship between expectation and outcome was not confined to laboratory settings but was visible across decades of actual life.

"Voodoo Death" and Extreme Nocebo

Walter Cannon's 1942 paper "Voodoo Death" documented cases in indigenous communities where individuals died after being cursed by a shaman. Cannon proposed that extreme fear could activate a "fight or flight" response so overwhelming that death resulted from cardiovascular collapse. While his specific mechanism has been debated, the phenomenon of psychologically-mediated sudden death — takotsubo cardiomyopathy (stress cardiomyopathy) and fatal arrhythmias triggered by extreme fear — is now medically documented.

Sudden death following psychological shock is a real phenomenon. Mortality rates spike in the days following natural disasters. Cardiac deaths increase on days with extreme emotional events. A study by Trichopoulos and colleagues found that deaths from cardiovascular causes rose significantly on the day of the 1981 Athens earthquake and the two days following. The nocebo effect at the extreme end of the spectrum is physiologically lethal.

Takotsubo cardiomyopathy — sometimes called "broken heart syndrome" — was first described by Japanese researchers in 1990 and is now a well-established clinical entity, occurring in approximately 2% of patients presenting with acute coronary syndrome. It is caused by massive sympathetic nervous system activation in response to emotional shock, producing transient left ventricular dysfunction in the absence of coronary artery disease. The emotional event is the cause. The cardiac damage is real.

How to Minimize Nocebo Effects Without Sacrificing Honesty

There is no ethical or practical case for withholding information from patients. But there are evidence-based approaches to minimize nocebo induction:

For Clinicians

Use positive framing where truthful: Instead of "You might feel severe pain," consider "Most people find this uncomfortable but manageable."

Provide base rates: "About 3% of patients experience this" is less alarming than simply listing the side effect. Base-rate framing activates different cognitive processing than open-ended risk descriptions: it allows the patient to locate themselves on a distribution rather than imagine worst-case scenarios.

Lead with benefit: Structure consent conversations to discuss benefits before risks. This primes the patient's cognitive and emotional state in a way that colors subsequent risk processing.

Build therapeutic alliance: Patients with strong trust in their clinician show reduced nocebo responses. The relationship itself is pharmacologically active. Time invested in building a genuine, caring relationship is time invested in minimizing the adverse event burden of every treatment that follows.

Normalize and contextualize: Brief, expected sensations should be framed as signs of the treatment working, not as problems. The reframe from "discomfort" to "your body responding" is not deceptive — it is accurate and has documented benefits for pain tolerance and treatment adherence.

Authorized deception (contested): Some ethicists have proposed informed forms of positive framing where the patient is told the intervention might cause either beneficial or neutral sensations, without specific nocebo-triggering details. This is controversial and not standard practice, but the ethical debate has produced useful frameworks for thinking about the obligations of framing.

For Patients

Be cautious with symptom-searching: Reading detailed lists of possible side effects before taking a medication can increase the probability of experiencing them. This is not a reason to be uninformed, but it is a reason to be deliberate about when and how you acquire this information.

Understand the base rate: A side effect listed at 1% incidence affects 99% of people favorably. Context matters.

Trust calibration: Research consistently shows that therapeutic context — a calm, supportive clinical environment — reduces nocebo responses. The setting in which you receive treatment is not irrelevant. Seeking care from clinicians who take time to explain, listen, and build confidence is not merely a preference issue — it has measurable effects on treatment outcomes.

Notice catastrophizing: Nocebo effects in everyday life are often amplified by the tendency to catastrophize — to imagine worst-case outcomes in detail. Recognizing this and deliberately considering more likely outcomes reduces the biological activation that catastrophizing produces.

Why Nocebo Research Matters Beyond Medicine

The nocebo effect has implications that extend well beyond drug trials and clinical communication.

In organizational life: Employees who are told that a new process will be painful and disruptive tend to experience it that way more intensely than employees given the same process with a constructive framing. The expectation shapes the experience. Research on organizational change management consistently finds that how change is communicated — the framing, the sequence, the level of confidence expressed by leaders — predicts employee experience of the change independently of its actual content.

In education: Students told that a test is unusually difficult perform worse than equivalent students told it is straightforward. Stereotype threat — the documented phenomenon where activating awareness of a negative stereotype about one's group impairs performance — is a nocebo mechanism operating through social expectation. Research by Steele and Aronson (1995) demonstrated that simply mentioning the racial dimension of a test before administering it to Black students reduced their performance relative to a condition where the test was described in race-neutral terms. The expectation activated by social context was the variable. Subsequent research has documented stereotype threat effects across gender, age, social class, and numerous other social identities.

In technology adoption: Users primed to expect frustrating software find it more frustrating. Onboarding that emphasizes complexity activates nocebo-style aversion that shapes the user experience of the actual product, not just the expectation.

In public health communication: Vaccine hesitancy is partly a nocebo problem. When side effect communication is not carefully calibrated, it can generate the very reactions it is meant to disclose. The SAMSON trial statin findings have direct parallels in vaccine uptake research. Public health communicators who lead with extensive descriptions of adverse events, without adequate contextualization, may be creating the conditions for the very hesitancy they are trying to address through transparency.

What the Nocebo Effect Reveals About the Mind-Body Problem

For a long time, Western medicine operated on a rough assumption that mental states and physical states are separate categories. The body is a machine; the mind is a passenger. The nocebo effect is one of the clearest demonstrations that this model is wrong.

Expectation is not a mental epiphenomenon. It is a biological process that modifies hormone levels, changes pain sensitivity, alters immune function, and under extreme conditions can kill. The mind is not separate from the body — it is implemented in the body, and it acts on the body continuously.

This does not make the nocebo effect mysterious. It is a predictable output of systems that evolved to prepare organisms for anticipated threats. The brain's job is to model the future and pre-configure the body for what is coming. When the modeled future contains harm, the body begins preparing for harm — and in doing so, sometimes creates it.

The philosopher of biology Peter Godfrey-Smith has argued that the predictive function of the nervous system — its role in anticipating states of the world rather than merely reacting to them — is one of the most fundamental features of animal cognition. Nocebo is this predictive function applied to health: the brain models expected harm, and the modeled harm activates the same physiological machinery as actual harm. Evolution built a threat-preparation system so efficient that it sometimes cannot distinguish anticipated from actual danger.

Understanding nocebo is not just academically interesting. It is one of the most practically significant phenomena in all of medicine, with direct implications for how treatments should be communicated, how clinical trials should be designed, how patients should receive information, and how society should talk about health risks.

The words a doctor uses when explaining a treatment are not neutral. They are, in a precise pharmacological sense, part of the treatment.

Summary

The nocebo effect is the induction of real physiological harm through negative expectation, suggestion, or belief
It is biologically mediated: CCK, cortisol, opioid systems, and HPA axis are all demonstrably involved
Warning label disclosure can induce the side effects it describes — documented in finasteride, statins, beta-blockers, and vaccines
The SAMSON trial found 90% of statin-attributed muscle pain was nocebo, with significant public health implications for cardiovascular medication adherence
Mass psychogenic illness is nocebo operating through social contagion, mediated by the same social learning mechanisms that transmit behavioral norms
Clinicians can minimize nocebo through positive framing, base-rate disclosure, consent framing reform, and therapeutic alliance
At extremes, nocebo can contribute to cardiac events and death through verified mechanisms including takotsubo cardiomyopathy and fatal arrhythmia
Stereotype threat in educational and professional contexts is a social nocebo mechanism with well-documented performance consequences
The nocebo effect demonstrates that expectation is a biological variable, not a mental abstraction — and that language, relationship, and context are themselves pharmacologically active

Frequently Asked Questions

What is the nocebo effect?

The nocebo effect occurs when negative expectations, fear, or suggestion cause real, measurable harm to a person's health. The word comes from Latin meaning 'I shall harm,' in contrast to placebo ('I shall please'). A patient who expects to feel nauseated after taking a pill may genuinely experience nausea, even if the pill is inert.

How is the nocebo effect different from the placebo effect?

The placebo effect produces beneficial outcomes from positive expectations or inert treatments. The nocebo effect produces harmful outcomes from negative expectations. Both involve the same underlying mechanism: the brain's anticipatory processing translates expectation into measurable physiological change. The nocebo effect is generally less studied but potentially more clinically significant because it can cause patients to abandon effective treatments.

Can reading a drug's warning label make you experience side effects?

Research strongly suggests yes. Studies of patients informed of possible side effects before treatment show higher rates of those exact side effects compared to patients not informed. A 2009 study of finasteride for benign prostatic hyperplasia found that patients who were warned about sexual dysfunction experienced it at nearly twice the rate of patients who were not informed. This is the nocebo effect in clinical practice.

What happens in the brain during the nocebo effect?

Neuroimaging and pharmacological studies show nocebo effects involve real neurobiological changes. Negative expectations activate anticipatory anxiety circuits in the prefrontal cortex and amygdala, trigger the hypothalamic-pituitary-adrenal axis (releasing stress hormones), and can reduce endogenous opioid activity. Cholecystokinin (CCK) has been identified as a key mediator: nocebo hyperalgesia can be blocked by CCK antagonists, confirming it is not merely psychological reporting bias.

Is the nocebo effect ethically challenging for doctors?

Yes. Informed consent requires disclosing side effects, but disclosure itself can cause those effects. This creates a genuine ethical tension between the legal and ethical obligation to inform patients and the clinical obligation to avoid harm. Some researchers propose 'authorized deception' or 'positive framing' strategies that satisfy disclosure requirements while minimizing nocebo induction, but these approaches are contested.